Clinical Trial

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

Name: Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL — clinical trial record (NCT07480863)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

In patients with previously untreated Marginal zone lymphoma (MZL), a treatment regimen of Orelabrutinib,Zuberitamab combined with Cyclophosphamide,Vincristine,Prednisoneacetatetablets is planned to be used.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-03-14.

Trial Details

NCT Number	NCT07480863
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences Collaborators: InnoCare Pharma Inc., BioRay Pharmaceutical Co., Ltd.
Conditions	Marginal Zone Lymphoma(MZL)
Enrollment	65 participants
Start Date	2025-10-01
Primary Completion	2029-10-01 (estimated)
Study Completion	2029-10-02 (estimated)
Updated on ClinicalTrials.gov	2026-04-02